<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00073866</url>
  </required_header>
  <id_info>
    <org_study_id>NU 01L2</org_study_id>
    <secondary_id>NU-01L2</secondary_id>
    <secondary_id>PHARMACIA-NU-01L2</secondary_id>
    <nct_id>NCT00073866</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase I/II Trial Of Weekly Irinotecan And Docetaxel With The Addition Of Celecoxib In Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Celecoxib may stop the growth of tumor cells by stopping blood flow&#xD;
      to the tumor. Combining celecoxib with combination chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of irinotecan and&#xD;
      docetaxel when given together with celecoxib and to see how well they work in treating&#xD;
      patients with advanced non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the recommended phase II dose of docetaxel and irinotecan in combination with&#xD;
           celecoxib in patients with advanced non-small cell lung cancer.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the response rate of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the progression-free and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Correlate angiogenesis markers (intratumoral microvessel density and vascular&#xD;
           endothelial growth factor [VEGF] expression and serum VEGF) and cyclooxygenase-2&#xD;
           expression with response and survival in patients treated with this regimen.&#xD;
&#xD;
        -  Correlate UGT1A1 genotype and CYP3A4 activity with the toxic effects of this regimen in&#xD;
           these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of docetaxel and irinotecan.&#xD;
&#xD;
        -  Phase I: Patients receive docetaxel IV over 60 minutes and irinotecan IV over 30 minutes&#xD;
           on days 1 and 8. Patients also receive oral celecoxib twice daily beginning on day 2.&#xD;
           Courses repeat every 21 days in the absence of disease progression or unacceptable&#xD;
           toxicity Cohorts of 3-6 patients receive escalating doses of docetaxel and irinotecan&#xD;
           until the recommended phase II dose is determined. The recommended phase II dose is&#xD;
           defined as the highest dose at which 0 of 3 or 1 of 6 patients experience dose-limiting&#xD;
           toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive treatment as in phase I at the recommended phase II dose.&#xD;
&#xD;
      Patients are followed every 3 months until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-70 patients (3-36 for phase I and 16-34 for phase II) will be&#xD;
      accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of non-small cell lung cancer (NSCLC) meeting 1 of the following criteria:&#xD;
&#xD;
               -  Stage IV&#xD;
&#xD;
               -  Stage IIIB with a malignant pleural effusion&#xD;
&#xD;
               -  Locally recurrent and/or persistent disease after locoregional therapy with or&#xD;
                  without systemic chemotherapy&#xD;
&#xD;
          -  Unidimensionally measurable disease&#xD;
&#xD;
               -  If the only site of measurable disease is in a previously irradiated area must&#xD;
                  have documented progression of disease in that area&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT less than 2.5 times upper limit of normal (ULN) (if alkaline phosphatase&#xD;
             is normal)&#xD;
&#xD;
          -  Alkaline phosphatase less than 4 times ULN (if AST and ALT are normal)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             treatment&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated squamous cell or&#xD;
             basal cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No diagnosis of peptic ulcer disease or gastritis/esophagitis within the past 60 days&#xD;
&#xD;
          -  No prior hypersensitivity to cyclooxygenase-2 (COX-2) inhibitors, nonsteroidal&#xD;
             anti-inflammatory drugs (NSAIDs), salicylates, sulfonamides, or drugs formulated with&#xD;
             polysorbate 80&#xD;
&#xD;
          -  No pre-existing grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  No concurrent medical condition that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 1 week since prior biologic therapy&#xD;
&#xD;
          -  Phase I patients:&#xD;
&#xD;
               -  Any number of prior biologic therapies allowed (e.g., chimeric antibodies or&#xD;
                  kinase inhibitors)&#xD;
&#xD;
          -  Phase II patients:&#xD;
&#xD;
               -  No prior biologic therapy for recurrent/metastatic disease&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No prior irinotecan or docetaxel&#xD;
&#xD;
          -  Phase I patients:&#xD;
&#xD;
               -  Up to 2 prior chemotherapy regimens for recurrent/metastatic disease allowed&#xD;
                  (chemona√Øve patients are also eligible)&#xD;
&#xD;
          -  Phase II patients:&#xD;
&#xD;
               -  At least 1 year since prior adjuvant or neoadjuvant chemotherapy for stage I-IIIA&#xD;
                  disease&#xD;
&#xD;
               -  No prior chemotherapy for recurrent/metastatic disease&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Less than 2 weeks of cumulative oral/IV corticosteroid use within the past 3 months&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior extensive-field radiotherapy for recurrent/metastatic&#xD;
             disease&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 60 days since prior treatment for peptic ulcer disease or&#xD;
             gastritis/esophagitis&#xD;
&#xD;
          -  No prior NSAIDs at a frequency of more than 3 times per week for a cumulative period&#xD;
             of more than 2 weeks within the past 30 days&#xD;
&#xD;
          -  No concurrent antiepileptics, cyclosporine, aspirin, or fluconazole&#xD;
&#xD;
          -  No concurrent NSAIDs&#xD;
&#xD;
          -  No other concurrent COX-2 inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athanassios Argiris, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Northwestern Health Care - Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silver Cross Hospital</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Argiris A, Kut V, Luong L, Avram MJ. Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer. Invest New Drugs. 2006 May;24(3):203-12.</citation>
    <PMID>16096702</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <disposition_first_submitted>February 16, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 18, 2011</disposition_first_posted>
  <last_update_submitted>July 10, 2012</last_update_submitted>
  <last_update_submitted_qc>July 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

